Idioma:

Determining Value in Health Technology Assessment: Stay the Course or Tack Away?

Caro, J. Jaime ; Brazier, John E. ; Karnon, Jonathan ; Kolominsky-Rabas, Peter ; McGuire, Alistair J. ; Nord, Erik ; Schlander, Michael

PharmacoEconomics, 2019-03, Vol.37 (3), p.293-299 [Periódico revisado por pares]

Cham: Springer International Publishing

Texto completo disponível

Citações Citado por

Enviar para

Título:
Determining Value in Health Technology Assessment: Stay the Course or Tack Away?
Autor: Caro, J. Jaime ; Brazier, John E. ; Karnon, Jonathan ; Kolominsky-Rabas, Peter ; McGuire, Alistair J. ; Nord, Erik ; Schlander, Michael
Assuntos: Analysis ; Biomedical Technology - economics ; Cost analysis ; Cost benefit analysis ; Current Opinion ; Decision making ; Decision Support Techniques ; Economic aspects ; Efficiency ; Health Administration ; Health care industry ; Health Economics ; Health technology assessment ; Humans ; Illnesses ; Intervention ; Medical care, Cost of ; Medicine ; Medicine & Public Health ; Methods ; Mortality ; Opportunity costs ; Pharmaceutical industry ; Pharmacoeconomics ; Pharmacoeconomics and Health Outcomes ; Preferences ; Public Health ; Quality ; Quality of life ; Quality of Life Research ; Quality-Adjusted Life Years ; Society ; Tariffs ; Technology assessment ; Technology Assessment, Biomedical - methods
É parte de: PharmacoEconomics, 2019-03, Vol.37 (3), p.293-299
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: The economic evaluation of new health technologies to assess whether the value of the expected health benefits warrants the proposed additional costs has become an essential step in making novel interventions available to patients. This assessment of value is problematic because there exists no natural means to measure it. One approach is to assume that society wishes to maximize aggregate health, measured in terms of quality-adjusted life-years (QALYs). Commonly, a single ‘cost-effectiveness’ threshold is used to gauge whether the intervention is sufficiently efficient in doing so. This approach has come under fire for failing to account for societal values that favor treating more severe illness and ensuring equal access to resources, regardless of pre-existing conditions or capacity to benefit. Alternatives involving expansion of the measure of benefit or adjusting the threshold have been proposed and some have advocated tacking away from the cost per QALY entirely to implement therapeutic area-specific efficiency frontiers, multicriteria decision analysis or other approaches that keep the dimensions of benefit distinct and value them separately. In this paper, each of these alternative courses is considered, based on the experiences of the authors, with a view to clarifying their implications.
Editor: Cham: Springer International Publishing
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Determining Value in Health Technology Assessment: Stay the Course or Tack Away?

Caro, J. Jaime ; Brazier, John E. ; Karnon, Jonathan ; Kolominsky-Rabas, Peter ; McGuire, Alistair J. ; Nord, Erik ; Schlander, Michael

Cham: Springer International Publishing

Buscando em bases de dados remotas. Favor aguardar.